SAB Biotherapeutics, Inc.
SABSNasdaqCIK 1833214HealthcareFiscal year ends Dec 31
Reports and events: 131 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1312:36 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-419769 |
| 2026-08-1020:27 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-26-000220 |
| 2026-08-0611:56 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-336783 |
| 2026-07-0712:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-296936 |
| 2026-06-1820:35 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-275976 |
| 2026-05-1211:35 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-218195 |
| 2026-05-0420:35 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-204125 |
| 2026-04-3020:45 ET | DEF 14A | Proxy statementPeriod 2026-06-18 | 0001193125-26-197607 |
| 2026-04-2212:13 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-168569 |
| 2026-03-2320:25 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-26-000079 |
| 2026-03-1900:28 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-114730 |
| 2026-03-1120:43 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-26-000072 |
| 2026-03-1011:35 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-099376 |
| 2026-03-0921:10 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001833214-26-000003 |
| 2026-01-1221:47 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-010515 |
| 2026-01-0713:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-005487 |
| 2025-12-2921:00 ET | 8-K | 8.01 Other events | 0001193125-25-335267 |
| 2025-11-1422:43 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-280572 |
| 2025-10-0320:26 ET | SCHEDULE 13D | Ownership report, active investor | 0001346824-25-000015 |
| 2025-09-3020:35 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-25-225119 |
| 2025-09-2620:45 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-25-220721 |
| 2025-08-2921:23 ET | DEF 14A | Proxy statementPeriod 2025-09-26 | 0001193125-25-192856 |
| 2025-08-0711:30 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-104566 |
| 2025-07-2111:31 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-097078 |
| 2025-07-1721:00 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-096645 |
| 2025-06-0221:00 ET | DEF 14A | Proxy statementPeriod 2025-07-17 | 0000950170-25-080361 |
| 2025-05-0912:42 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-067554 |
| 2025-03-3122:00 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-046994 |
| 2025-02-0522:00 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0000950170-25-014627 |
| 2025-01-2812:11 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-009474 |
| 2024-11-0622:00 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-122443 |
| 2024-09-0912:21 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-104564 |
| 2024-08-0820:30 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-094084 |
| 2024-07-3112:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-088247 |
| 2024-06-2721:29 ET | 8-K | 5.07 Shareholder vote results | 0000950170-24-078622 |
| 2024-05-3122:49 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-066856 |
| 2024-05-3021:15 ET | DEF 14A | Proxy statementPeriod 2024-05-22 | 0000950170-24-066767 |
| 2024-05-2111:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-062656 |
| 2024-05-2020:01 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-062367 |
| 2024-05-0822:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-054868 |
| 2024-04-1521:15 ET | 8-K | 7.01 Regulation FD disclosure | 0000950170-24-044497 |
| 2024-03-2913:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-038429 |
| 2024-03-2921:43 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-038219 |
| 2024-03-0821:30 ET | 8-K | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-028666 |
| 2024-02-0212:53 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-010093 |
| 2024-01-2621:15 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-24-007941 |
| 2024-01-2522:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-007480 |
| 2024-01-1921:21 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-005793 |
| 2024-01-0314:00 ET | 8-K | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-000543 |
| 2023-12-1814:34 ET | DEF 14A | Proxy statementPeriod 2023-12-18 | 0000950170-23-070950 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 14:57 ET. Listed shows no prices and gives no investment advice.